OBJECTIVE: Leptin, the circulating product of the human ob gene, may play role in control of appetite and metabolic rate. We screened the proximal promoter area of the ob gene for mutations and common polymorphisms in order to ®nd out whether genetic variation in the regulatory area of this gene plays a role in human obesity. DESIGN: The technique of single-strand-conformation polymorphism (SSCP) was applied to screen for the promoter area of the ob gene for genetic alterations in morbidly obese patients. SUBJECTS: A total of 249 morbidity obese (present or past body mass index [BMI] ! 40 kg/m 2 ) and 141 lean (BMI 25 kg/m 2 ) subjects. MEASUREMENTS: DNA analysis was carried out using a single-strand conformation polymorphism (SSCP) technique and PCR followed by digestion with the restriction enzyme BssHII. Leptin was determined by radioimmunoassay in obese subjects. Serum lipids, glucose and insulin concentrations in the obese subjects were also determined. RESULTS: A new polymorphism C(-188)A was identi®ed in the promoter region of the ob gene. This polymorphism was detected with allelic frequencies of 0.06 in morbidly obese subjects and 0.09 in lean controls (P 0.28). Initial studies failed to show an association of this polymorphism with serum leptin, response to treatment for obesity, history and extent of weight gain, or serum insulin, glucose of lipid concentrations. CONCLUSIONS: We have identi®ed a common polymorphism in the promoter area of the human ob gene which appears to be very useful for genetic association and linkage studies. Further studies are needed to elucidate its potential role in the regulation of the human ob gene and in human metabolic disorders.
Introduction
Leptin is encoded by the human ob gene located in chromosome 7q31, 1 appears to be produced exclusively by adipose tissue, and is circulating in amounts re¯ecting the fat content of an individual. 2, 3 It is not clear, however, whether the increase of serum leptin concentrations in obese subjects represents a primary disorder of leptin production or merely re¯ects a leptin resistance state. In a monogenic animal model of obesity, ob/ob mice, morbid obesity was found to result from mutations of the ob gene. 4 Attempts to identify mutations in the coding region of the human ob gene have so far failed to demonstrate a similar causal relationship in human forms of obesity.
5±7
Molecular cloning of candidate genes for human obesity, such as those encoding leptin, 4 and the leptin receptor 8 has enabled direct molecular genetic studies of their role in disorders of abnormal weight gain. We decided to screen for mutations and common polymorphisms in the promoter area of the human ob gene in order to ®nd out whether genetic variation in the regulatory area of this gene may play a role in human obesity.
Methods

Subjects
A total of 249 obese subjects (67 males; 182 females) were examined. These subjects were originally referred to The Internal Medicine Outpatient Ward of the Helsinki University Central Hospital for a weight reduction program during the years 1989± 1995, and detailed description of their demographic and clinical characteristics is provided in our previous paper. 9 In short, admission criteria at the initial recruitment, included a BMI ! 40 kg/m 2 and age between 18 and 60 y (mean age 46 AE 9 y). Their mean (AE s.d.) BMI at the initial admission was 45.4 AE 5.6 kg/m 2 . At the time of the present study the mean BMI was 42.9 AE 7.1, with a range of 27± 81 kg/m 2 . Fifty-nine subjects had NIDDM, and 153 were treated for hypertension. Blood samples were collected following a 12 h fast, for serum leptin, insulin, glucose and lipid measurements as well as DNA isolation. In addition, each subject completed a structured questionnaire including details on general medical history and drug treatment as well as history of weight development (birth weight, weight at the age of 20 y, and the highest body weight ever attained). Most of the subjects also participated in a 16 week reduction treatment program including a very-low calorie diet (VLCD) regimen in the years 1989±1995. Blood samples were also collected from 141 apparently healthy lean controls (61 males; 80 females) all having BMI 25 kg/m 2 (mean 22.3 AE 1.9 kg/m 2 ). Their mean age was 40 AE 11 y. The protocol of this study was approved by the Ethical Review Committee of the Department of Medicine and written consent was obtained from every subject.
Mutation screening by single strand conformation polymorphism DNA was prepared from EDTA-anticoagulated venous blood samples using standard techniques. The promoter area of interest, extending from nucleotide (nt) 7408 to nt 6 of the ®rst intron of the human ob gene 10 was ®rst ampli®ed in two pieces using polymerase chain reaction (PCR). In the ®rst set of assays, primer A (5 H -AGGCCCCGCGAGGTGCA-CACT-3 H ) extending from nt 7168 to nt 7148 and primer B (5 H -CCTTACCTTGCAACCGTTGG-3 H ) extending from the sixth nt of the ®rst intron to nt 16 of the ®rst exon were used to amplify a proximal promoter sequence 203 base pairs (bp) in size, and in the second set of assays, primer C (5 H -CAACGAGGGCGCAGCCGTAT-3 H ) extending from nt 7408 to nt 7389 and primer D (5 H -AGTGTG-CACCTCG-CGGGGCCT-3 H ) extending from nt 7148 to nt 7168 were used to amplify a more distal promoter sequence of 261 bp. PCR was conducted in a volume of 50 ml containing 50 ng of template DNA, 200 mM of each dNTP, 50 pmol each of the primers and 0.8 U Dynazyme DNA polymerase (Finnzymes, Helsinki) in the buffer supplied by the manufacturer. After initial denaturation for 5 min at 95 C, 30 cycles (for 1 min each) at 95 C, 62 C (primers A and B), or 66 C (primers C and D), and 72 C were used. Analysis of single strand conformation polymorphism (SSCP) was conducted essentially as described by Orita et al 11 using 5% non-denaturating polyacrylamide sequencing gels containing 10% glycerol in 90 mM Tris-borate pH 8.3, 4 mM EDTA buffer. After electrophoresis at room temperature, the gel was transferred to a ®lter paper, dried in a vacuum slab dryer and subjected to autoradiography for 1±3 d at 770 C.
DNA sequencing
Both strands of the PCR products were sequenced by the dideoxy chain termination technique of Sanger et al. 12 The products of the sequencing reactions were electrophoresed on 6% polyacrylamide gels and visualized by autoradiography.
Assay of the promoter polymorphism by PCR and restriction enzyme digestion
For routine screening of the variant nucleotide at the position 7188, DNA was ampli®ed with the primers C and D using PCR conditions described above. After PCR, aliquots (20 ml) of the samples were digested with the restriction enzyme BssHII (2U/sample) for 3 h at 50 C, followed by electrophoresis on a 10% polyacrylamide gel and visualization of the cleavage products by ethidium bromide staining.
Assays for serum leptin, insulin, glucose and lipids
Leptin concentration was determined with radioimmunoassay as previously described. 3 We have previously reported serum leptin concentrations in the present cohort of morbidly obese subjects and shown that they are directly correlated to BMI. 13 Serum glucose was measured by a commercial glucose dehydrogenase-technique and serum insulin by a double antibody radioimmunoassay (Pharmacia, Uppsala, Sweden). Serum concentrations of total cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides were measured using enzymatic techniques and commercial kits obtained from Boehringer (Mannheim, Germany).
Statistical analysis
Possible association of the categorical variables with the ob gene promoter genotypes were tested using Cochran's w 2 -test for trend. 14 Means of the quantitative traits in the different genotypes were compared using analysis of variance.
Results
DNA samples from 29 morbidly obese subjects with a present BMI ranging from 27±81 kg/m 2 were initially screened for SSCPs in the ob promoter region extending from nt 7408 to nt 6 of the ®rst intron. Three samples showed an apparently identical aberrantly migrating DNA fragment when the PCR fragment under study extended from nt 7408 to nt 7148 (Figure 1a) . No other abnormal SSCP signals were found under these conditions. Subsequently, all the remaining 220 DNA samples from obese individuals as well as the 141 control samples from lean subjects were screened for this SSCP pattern, and, in addition to a number of samples showing abnormal SSCP signals of apparently similar nature to those initially discovered, three samples were identi®ed with an SSCP pattern suggesting homozygosity for the underlying DNA alteration (Figure 1a ). Sequence analysis of the DNA sample of a patient homozygous for the SSCP shift revealed a single nucleotide change substituting A for C at position 7188 (for nucleotide numbering, see Ref. 10) , and a homozygous carrier The frequencies of the ob promoter genotypes CC, CA and AA in the lean controls (0.84, 0.16 and 0.01, respectively) were not signi®cantly different from those in the morbidly obese subjects (0.88, 0.11 and 0.01, respectively), and the C and A allele frequencies in the lean controls (0.91 and 0.09) and obese individuals (0.94 and 0.06) were likewise very similar (Table 1 ). There were only three individual (two obese, one lean) with the genotype AA. When obese individuals with the genotypes CC, CA and AA were compared to each other in regard to history of weight development, no signi®cant genotype-related differences were found (Table 2 ). In morbidly obese women, serum leptin concentrations were likewise similar in the three genotypes, while among obese men those with the genotype CA had somewhat higher (P 0.024) serum leptin than those with the genotype CC; there were, however, only nine males with the genotype CA (Figure 3 ). Serum insulin, glucose and lipid concentrations did not differ either according to genotype ( Table 2) . The results were similar if only those 120 subjects without a medica- (Table 3) .
Discussion
This paper describes a hitherto unrecognized singlenucleotide variation in the promoter area of the human ob gene. The polymorphism is relatively common in the population, with allelic frequencies approximately 91% and 9%, and thus provides a useful marker for genetic studies on the role of leptin in human metabolic disorders. The human ob gene was mapped to chromosome 7q31.3, consists of three exons and two introns, and spans approximately 20 kb. 1 As little as 217 bp the ob gene upstream sequences were shown to be suf®cient to drive high-level, adipocyte-speci®c expression of the ob gene. 15 In fact, transfection experiments indicated that, as a gene promoter; the proximal 300 bpregion was more active than a more extended 3000 bp fragment, suggesting that the regions upstream of nt 7300 may contain elements inhibitory for transcription. 10 Even if the C(7188)A substitution itself does not appear to abolish or create sites for interaction with proposed transcription factors, it is of interest that there are several putative regulatory sites in its close vicinity: Sp1 binding sites from nt 792 to 7104, from nt 7123 to 7128 and from nt 7344 to 7353, C/EBPa binding sites from nt 746 to 754 and from nt 7291 to 7299, and an AP2 binding site from nt 7135 to 7142. 1, 10, 15 Results from transfec- Figure 3 Serum leptin levels in 228 morbidly obese subjects according to the ob gene promoter genotype CC, CA or AA. Data for male and female subjects are shown separately. Insulin (pmol/l)/Glucose (mmol/l). 16 ob promoter constructs emphasize the role of C/EBPa in particular as a regulator of the ob gene expression.
Two recent sib-pair studies provided evidence for linkage of the markers at human ob gene¯anking region with extreme obesity. 17, 18 Direct structural studies have, however, failed to identify mutations in the coding region of the ob gene of obese human individuals. 5±7 An exception was the Val94 3 Met point mutation found in the leptin molecule of a single obese subject, but the pathophysiological consequences of this mutation was not reported. 19 The fact that serum leptin concentrations among obese individuals, even if showing a signi®cant linear correlation to BMI, vary up to ten-fold in subjects of the same weight 2, 3, 20 prompted us to start a search for mutations and polymorphisms in the regulatory area of the human ob gene.
The C(7188)A substitution we identi®ed is the ®rst ob gene promoter variation so far reported. Results of our genetic association study suggest that this polymorphism is not causally related to extreme human obesity, nor is in linkage disequilibrium with other putative alterations of the human ob gene suf®cient to cause abnormal weight gain, at least in the Finnish population. We did not ®nd any consistent relation between the promoter polymorphism and serum leptin concentrations in obese subjects, suggesting that the effect of this DNA variation on the ob promoter activity in vivo may not be particularly strong. The speci®c effect, if any, of the C(7188)A substitution on the ob gene promoter activity in vitro remains to be explored.
Conclusions
We have identi®ed a common polymorphism in the promoter area of the human ob gene which appears to be very useful for genetic association and linkage studies. Initial studies failed to show an association of this polymorphism with history and extent of weight gain, or serum insulin, glucose or lipid concentrations. Whether it affects the extent of basal or transcription factor-regulated ob gene expression remains to be investigated.
